Sphingomyelin metabolism controls the shape and function of the Golgi cisternae
Abstract
The flat Golgi cisterna is a highly conserved feature of eukaryotic cells, but how is this morphology achieved and is it related to its function in cargo sorting and export? A physical model of cisterna morphology led us to propose that sphingomyelin (SM) metabolism at the trans-Golgi membranes in mammalian cells essentially controls the structural features of a Golgi cisterna by regulating its association to curvature-generating proteins. An experimental test of this hypothesis revealed that affecting SM homeostasis converted flat cisternae into highly curled membranes with a concomitant dissociation of membrane curvature-generating proteins. These data lend support to our hypothesis that SM metabolism controls the structural organization of a Golgi cisterna. Together with our previously presented role of SM in controlling the location of proteins involved in glycosylation and vesicle formation, our data reveal the significance of SM metabolism in the structural organization and function of Golgi cisternae.
Article and author information
Author details
Funding
Ministerio de Economía y Competitividad (Severo Ochoa Programme SEV-2015-240522)
- Felix Campelo
- María García-Parajo
H2020 European Research Council (Advanced Grant 268692)
- Vivek Malhotra
Ministerio de Economía y Competitividad (Severo Ochoa Programme SEV-2012-0208)
- Vivek Malhotra
Ministerio de Economía y Competitividad (BFU2015-73288-JIN AEI/FED)
- Felix Campelo
- María García-Parajo
Fundación Cellex
- Felix Campelo
- María García-Parajo
Human Frontier Science Program (GA RGP0027/2012)
- María García-Parajo
European Commission (FP7-NANO-VISTA GA 288263)
- María García-Parajo
Institució Catalana de Recerca i Estudis Avançats
- María García-Parajo
- Vivek Malhotra
Israel Science Foundation (758/11)
- Michael M Kozlov
Ministerio de Economía y Competitividad (Plan Nacional FIS2014-56107-R)
- María García-Parajo
Ministerio de Economía y Competitividad (Plan Nacional BFU2013-44188-P)
- Vivek Malhotra
Ministerio de Economía y Competitividad (Consolider CSD2009-00016)
- Vivek Malhotra
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Copyright
© 2017, Campelo et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,810
- views
-
- 704
- downloads
-
- 42
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cell Biology
Niemann–Pick disease type C (NPC) is a devastating lysosomal storage disease characterized by abnormal cholesterol accumulation in lysosomes. Currently, there is no treatment for NPC. Transcription factor EB (TFEB), a member of the microphthalmia transcription factors (MiTF), has emerged as a master regulator of lysosomal function and promoted the clearance of substrates stored in cells. However, it is not known whether TFEB plays a role in cholesterol clearance in NPC disease. Here, we show that transgenic overexpression of TFEB, but not TFE3 (another member of MiTF family) facilitates cholesterol clearance in various NPC1 cell models. Pharmacological activation of TFEB by sulforaphane (SFN), a previously identified natural small-molecule TFEB agonist by us, can dramatically ameliorate cholesterol accumulation in human and mouse NPC1 cell models. In NPC1 cells, SFN induces TFEB nuclear translocation via a ROS-Ca2+-calcineurin-dependent but MTOR-independent pathway and upregulates the expression of TFEB-downstream genes, promoting lysosomal exocytosis and biogenesis. While genetic inhibition of TFEB abolishes the cholesterol clearance and exocytosis effect by SFN. In the NPC1 mouse model, SFN dephosphorylates/activates TFEB in the brain and exhibits potent efficacy of rescuing the loss of Purkinje cells and body weight. Hence, pharmacological upregulating lysosome machinery via targeting TFEB represents a promising approach to treat NPC and related lysosomal storage diseases, and provides the possibility of TFEB agonists, that is, SFN as potential NPC therapeutic candidates.
-
- Cell Biology
- Developmental Biology
A study in mice reveals key interactions between proteins involved in fibroblast growth factor signaling and how they contribute to distinct stages of eye lens development.